You are here

Nefazodone HCl Approved by FDA

CORONA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for nefazodone hydrochloride tablets in the 100 mg, 150 mg, 200 mg and 250 mg strengths. Nefazodone hydrochloride is the generic equivalent of Bristol-Myers Squibb's Serzone® and is indicated for the treatment of depression. For the 12-months ending June 2003, Serzone® had sales of approximately $220 million for all strengths, according to IMS data. Watson's nefazodone hydrochloride product will be launched immediately, making it the Company's 21st product launched in 2003.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission